Medeor Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Debt - PPP

  • Investors
  • 7

Medeor Therapeutics General Information

Description

Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.

Contact Information

Website
www.medeortx.com
Formerly Known As
SERC Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 611 Gateway Boulevard
  • Suite 120
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • 611 Gateway Boulevard
  • Suite 120
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medeor Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Debt - PPP 29-Apr-2020 Completed Generating Revenue
5. Grant 22-Jan-2018 Completed Generating Revenue
4. Later Stage VC (Series B) 27-Nov-2017 Completed Generating Revenue
3. Early Stage VC (Series A) 16-Oct-2015 Completed Generating Revenue
2. Early Stage VC 02-Oct-2013 $1.55M $2.55M Completed Generating Revenue
1. Seed Round 11-Jan-2013 $1M $1M Completed Generating Revenue
To view Medeor Therapeutics’s complete valuation and funding history, request access »

Medeor Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
Seed 1 1,291,667 $0.000100 8% $1.2 $1.2 1x $1.2 4.67%
Seed 1,000,000 $0.000100 8% $1 $1 1x $1 3.61%
To view Medeor Therapeutics’s complete cap table history, request access »

Medeor Therapeutics Patents

  • 37

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 7

    Pending

  • Expiring in next 12 mo

Medeor Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240108655-A1 Methods of producing mixed chimerism after a solid organ transplant Pending 13-Sep-2022
US-20230201256-A1 Calcineurin inhibitor to improve cd3+cell survival to thereby facilitate engraftment of donor cd34+ cells in a recipient Pending 21-May-2020
US-20220305057-A1 Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells Pending 06-Jun-2019
EP-3980036-A4 Methods of making cellular products by post-mortem mobilization and harvesting of hematopoietic cells Inactive 06-Jun-2019
EP-3980036-A1 Methods of making cellular products by post-mortem mobilization and harvesting of hematopoietic cells Inactive 06-Jun-2019 A61K35/28
To view Medeor Therapeutics’s complete patent history, request access »

Medeor Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
California Institute for Regenerative Medicine Government
120 Capital Venture Capital Minority
6 Dimensions Capital Venture Capital Minority
RA Capital Management Venture Capital Minority
Sofinnova Investments Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Medeor Therapeutics FAQs

  • When was Medeor Therapeutics founded?

    Medeor Therapeutics was founded in 2012.

  • Where is Medeor Therapeutics headquartered?

    Medeor Therapeutics is headquartered in South San Francisco, CA.

  • What industry is Medeor Therapeutics in?

    Medeor Therapeutics’s primary industry is Biotechnology.

  • Is Medeor Therapeutics a private or public company?

    Medeor Therapeutics is a Private company.

  • What is Medeor Therapeutics’s current revenue?

    The current revenue for Medeor Therapeutics is .

  • How much funding has Medeor Therapeutics raised over time?

    Medeor Therapeutics has raised $67.5M.

  • Who are Medeor Therapeutics’s investors?

    California Institute for Regenerative Medicine, 120 Capital, 6 Dimensions Capital, RA Capital Management, and Sofinnova Investments are 5 of 7 investors who have invested in Medeor Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »